checkAd

    Novoheart - stem cell biotechnology - bioartificial human heart - 500 Beiträge pro Seite

    eröffnet am 03.12.17 19:26:01 von
    neuester Beitrag 31.05.18 15:30:29 von
    Beiträge: 31
    ID: 1.268.660
    Aufrufe heute: 0
    Gesamt: 1.086
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 03.12.17 19:26:01
      Beitrag Nr. 1 ()
      Bin gespannt ob sich hier jemand findet um über den Titel zu diskutieren. 😀

      Finde den Ansatz mega interessant - gerade für die forschenden Pharariesen - denn in der Forschung geht viel Geld in die Binsen wg. Nebenwirkungen welche erst am Menschen sichtbar werden.

      Mit diesen "schlagenden Herzen" lässt sich da schon einiges in der Präklinik testen und viel, viel Geld sparen.
      Avatar
      schrieb am 04.12.17 00:45:37
      Beitrag Nr. 2 ()
      habe mir den Titel-Pre-IPO- auch schon bisschen angesehen.
      3 Antworten
      Avatar
      schrieb am 04.12.17 05:38:57
      Beitrag Nr. 3 ()
      Antwort auf Beitrag Nr.: 56.353.358 von Popeye82 am 04.12.17 00:45:37Ich bin über einen Artikel in der "Welt" auf die Aktie aufmerksam geworden. Habe mir mal ein pasr Stücke ins Depot gelegt.
      2 Antworten
      Avatar
      schrieb am 04.12.17 13:31:07
      Beitrag Nr. 4 ()
      Avatar
      schrieb am 04.12.17 13:32:44
      Beitrag Nr. 5 ()
      Antwort auf Beitrag Nr.: 56.353.526 von gunar_s am 04.12.17 05:38:57die story ist sehr interessant finde ich....

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 04.12.17 18:27:59
      Beitrag Nr. 6 ()
      Antwort auf Beitrag Nr.: 56.353.526 von gunar_s am 04.12.17 05:38:57nach Einiger Zeit tauchen in Diesen Threads meist die "SDR" Psychopathen("Geschädigten/Traumatisierten") auf.
      deren Weltbilder(+AnalyseABILITIES) sind so durch die Gülle gezogen,
      da kannst Du eine sinnbringende Diskussion normalerweise vergessen.
      also wenn ich mich für die Aktie entscheiden würde, müsste ich mich nicht "zigmal melden" im Faden.
      Avatar
      schrieb am 05.12.17 09:01:33
      Beitrag Nr. 7 ()
      Scheinbar haben Sie auch schon eine Kooperation mit einem "Global Pharma Partner" (siehe Finanzbericht zum "Fiscal Jahr 2017" welches am 30.06.17 geendet hat)

      Der Global Pharma Partner soll seinen Sitz wohl lt. Spekulationen in New York haben. (Pfizer???)
      Avatar
      schrieb am 06.12.17 19:24:38
      Beitrag Nr. 8 ()
      3 Antworten
      Avatar
      schrieb am 07.12.17 06:14:06
      Beitrag Nr. 9 ()
      Antwort auf Beitrag Nr.: 56.380.918 von Popeye82 am 06.12.17 19:24:38Suuuper Interview - wusste bisher gar nicht, dass due Firma auch Herzen mit Fehlern/Krankheiten nachbilden kann. Wow, was hier für Chancen drin liegen. :D:D
      2 Antworten
      Avatar
      schrieb am 14.12.17 01:53:03
      Beitrag Nr. 10 ()
      Avatar
      schrieb am 14.12.17 08:53:09
      Beitrag Nr. 11 ()
      Antwort auf Beitrag Nr.: 56.384.095 von gunar_s am 07.12.17 06:14:06http://www.sharedeals.de/2017/11/novoheart-kommerzielle-skal…
      1 Antwort
      Avatar
      schrieb am 14.12.17 19:12:35
      Beitrag Nr. 12 ()
      Antwort auf Beitrag Nr.: 56.444.447 von Papiga13 am 14.12.17 08:53:09was Eines Der Probleme bei deutschen Artikeln ist: dass "so"viel, vom Originalen, verloren geht.
      das-und Wie "Nah" Sie eben NICHT dran sind- kannst Du bei dt. Medien über internationale Themen/Firmen/Artikelkopiererei(uswusw) wahnsinnig, wahnsinnig merken.
      Avatar
      schrieb am 16.12.17 13:14:57
      Beitrag Nr. 13 ()
      1 Antwort
      Avatar
      schrieb am 16.12.17 13:24:23
      Beitrag Nr. 14 ()
      Antwort auf Beitrag Nr.: 56.467.283 von gunar_s am 16.12.17 13:14:57sie wirken so sprachLOS.

      trauen Sie sich!!
      Avatar
      schrieb am 16.12.17 13:54:00
      Beitrag Nr. 15 ()
      3 Antworten
      Avatar
      schrieb am 16.12.17 13:55:56
      Beitrag Nr. 16 ()
      Antwort auf Beitrag Nr.: 56.467.460 von gunar_s am 16.12.17 13:54:00Weiße Schrift auf weißem Grund?
      2 Antworten
      Avatar
      schrieb am 16.12.17 13:56:17
      Beitrag Nr. 17 ()
      Mist, das mit dem youtubevideo klappt nicht bei mir :-(

      Dann gibts den Link halt so!


      https://youtu.be/Bgu6wgtGuJc
      Avatar
      schrieb am 16.12.17 14:22:36
      Beitrag Nr. 18 ()
      Antwort auf Beitrag Nr.: 56.467.478 von question-mark am 16.12.17 13:55:56der Mann hat nicht Viel mitzuteilen in Seinem Leben.
      Avatar
      schrieb am 20.12.17 14:28:06
      Beitrag Nr. 19 ()
      gibt es was Neues ? Bin nur gering investiert, halte den Wert aber auf alle Fälle bis Q1 -
      mal sehen was dann ansteht.
      Avatar
      schrieb am 22.12.17 03:54:24
      Beitrag Nr. 20 ()
      Antwort auf Beitrag Nr.: 56.467.478 von question-mark am 16.12.17 13:55:56neee,
      ich weiss Übrigens Was Das ist.
      mir auch schonmal passiert:
      Aufnahme vom Weissen Haus!!
      Avatar
      schrieb am 16.01.18 14:24:31
      Beitrag Nr. 21 ()
      Avatar
      schrieb am 16.01.18 14:25:07
      Beitrag Nr. 22 ()
      Avatar
      schrieb am 17.01.18 04:39:36
      Beitrag Nr. 23 ()
      http://www.novoheart.com/global/press/detail/21

      "Novoheart Files Patent Application on Three-Tier Drug Screening System After Successful Collaboration Contract with Global Pharma Company


      VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 16, 2018) - Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH) today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a three-tiered drug screening system with enhanced capability, sensitivity and accuracy for detecting pharmacological effects on heart contractility that cannot be achieved with conventional models. The application resulted from the Company's collaborative contract with a multi-national global pharma company ("Pharma"). The completion of this contract also led to a subsequent income-generating contract with the same Pharma to build a cardiac disease model using the MyHeart™ Platform. Further details on both will be announced separately.

      Owing to the lack of reliable human heart models, drug development is a notoriously lengthy, expensive and inefficient process, plagued with false negative and false positive results which lead to unacceptably high failure rates of >90%. The ability to reliably detect cardiac efficacy and toxicity early on during drug development is crucial for success; yet currently available tools are inadequate in terms of their accuracy and sensitivity.

      To answer the unmet demand, the Company developed its proprietary drug screening system which comprises two types of bioengineered tissue constructs from Novoheart's MyHeart™ Platform, utilized in a tiered fashion: the first stage of screening utilizes the human ventricular cardiac tissue strip (hvCTS) for identifying effects in larger numbers of drug candidates, followed by verification in the second stage using the sophisticated human ventricular cardiac organoid chamber (hvCOC, or "human heart-in-a-jar™"), an exclusive Novoheart technology whose three-dimensional architecture and best-in-class physiological readouts allow highly sensitive detection to avoid false negatives and positives. In combination with Novoheart's proprietary multi-organoid culturing and imaging platform, where the hvCOC is connected via a fluidic system to other tissue-engineered organoids such as liver, a third tier of screening will be performed to study effects of drug compounds at the systems level, all in the context of human physiology but without involving patients.

      "As a result of the successful collaboration with our global pharma partner, we have been able to develop a new drug screening system capable of selecting the best candidates based on their effects on human heart contractility. The proprietary system can be adapted for healthy as well as sick hearts, for screening of both toxicity and efficacy. Notably, it enables testing to be carried out with great precision and sensitivity, without the need for patient involvement." said Kevin Costa, CSO of Novoheart.

      "With the improved precision that is now accessible to those in drug development as a result of this new three-tier drug screening system, we expect to further enhance our ability to commercialize and bring tangible value to both our clients and investors," said Ronald Li, CEO of Novoheart. "We are in the process of securing additional partnerships and contracts with drug developers in order to continue to extend the reach of our technology and meet what are significant industry needs."

      About Novoheart:

      Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics.

      Also known as 'human heart-in-a-jar', Novoheart's bioartificial human heart constructs are created using state-of-the-art stem cell and bioengineering approaches, and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.

      The Company is listed on the TSX Venture Exchange (the "TSXV") under the symbol "NVH".

      Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."
      Avatar
      schrieb am 30.01.18 05:48:53
      Beitrag Nr. 24 ()
      Neues Video mit dem CEO auf youtube und der Facebookseite von Novoheart "Capital Ideas TV, Episode 29". Erträge werden schon generiert - welche in Laboratorien und neue Mitarbeiter investiert werden/wurden, Gespräche mit weiteren Interessenten laufen, global aufgestellt, Startklar zur Kommerzialisierung, ... 😀
      Avatar
      schrieb am 31.01.18 07:23:05
      Beitrag Nr. 25 ()
      Avatar
      schrieb am 14.02.18 16:14:06
      Beitrag Nr. 26 ()
      Avatar
      schrieb am 26.02.18 17:22:07
      Beitrag Nr. 27 ()
      Avatar
      schrieb am 08.03.18 19:44:23
      Beitrag Nr. 28 ()
      http://www.novoheart.com/global/press/detail/25
      "Novoheart’s Landmark, Peer-Reviewed Study Published, Recognizing the Effectiveness of the World’s First and Only Human Heart-in-a-Jar


      March 8, 2018 03:05 ET
      Novoheart’s Landmark, Peer-Reviewed Study Published, Recognizing the Effectiveness of the World’s First and Only Human Heart-in-a-Jar

      VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 8, 2018) - (TSX VENTURE:NVH)(FRANKFURT:3NH)

      “Human heart-in-a-jar” technology recognized by the scientific community for its unique ability to reproduce key physiological and pharmacological features of the native human heart, including clinically recognized responses to a variety of pharmacological compounds and interventions.
      The only tool available in the market that provides measurement of the clinically complex parameters of the human heart, being utilized by drug developers for accurate preclinical testing to predict the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.
      Novoheart has exclusive global rights to this IP protected world’s first technology.
      As the flagship technology of the Company’s MyHeartTM Platform, “human heart-in-a-jar” is being commercialized to pharmaceutical and biotech companies.

      Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) is pleased to announce that it has published a comprehensive study of the world's first human heart-in-a-jar, in the prestigious bioengineering journal Biomaterials. The peer-reviewed paper showcases the human heart-in-a-jar's unique ability to recapitulate multiple important and complex biological properties of the native human heart, including clinically recognized responses to a variety of pharmacological compounds and interventions.

      "This is an exciting milestone for the Company and we anticipate that the publication of this study will lead to significant additional interest from pharmaceutical partners in the MyHeart™ Platform," said Dr. Ronald Li, CEO of Novoheart. "In an industry where drug attrition and withdrawals are most commonly associated with cardiotoxicity, the 'human heart-in-a-jar' represents an unprecedented high-fidelity model of the human heart outside of the body, offering a new and compelling alternative to traditional animal models as litmus tests for selecting the best drug candidates to advance into clinical trials."

      The human ventricular cardiac organoid chamber (hvCOC), also known as "human heart-in-a-jar", is a truly three-dimensional, bioengineered miniature cardiac pump, representing a highly sophisticated bio-artificial heart construct exclusively available from Novoheart's MyHeart™ Platform. In this publication, the hvCOC is comprehensively characterized in detail, including its remarkable ability to simulate key characteristics and behaviors of the native human heart at the genetic, electrical and mechanical levels. As a result of its unique cardiomimetic configuration, the hvCOC also reproduces responses to a range of clinically tested therapeutics, including drug classes to which other existing stem cell-derived cell and tissue models are notoriously insensitive.

      The publication is the result of extensive research led by Novoheart's scientific co-founders, CEO Ronald Li and CSO Kevin Costa, in collaboration with a multinational team of investigators from Sweden's Karolinska Institutet (whose Nobel Assembly selects and awards Nobel Prizes in Physiology and Medicine), the University of Hong Kong, and the Icahn School of Medicine at Mount Sinai in Manhattan, New York, with part of the study performed under an industry-academia collaboration jointly funded by Novoheart and the Innovation and Technology Commission (ITC) of the Hong Kong government.

      "We are pleased to share with the scientific community the unique features of our hvCOC, including the ability to recapitulate pressure-volume and electrophysiological characteristics of the heart, and how it compares to other existing human cardiac cell and tissue models," said Dr. Kevin Costa, CSO of Novoheart. "The peer-reviewed article serves as a testimony to the quality and importance of the research, which is the fundamental groundwork behind the 'human heart-in-a-jar' model."
      Due to appear shortly in print, Novoheart’s publication, titled “Bioengineering an electro-mechanically functional miniature ventricular heart chamber from human pluripotent stem cells”, can be accessed online here.


      About Novoheart:

      Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as 'human heart-in-a-jar', Novoheart’s bioartificial human heart constructs are created using state-of-the-art stem cell and proprietary stem call and bioengineering approaches and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.

      Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

      Cautionary Note Regarding Forward-Looking Statements

      Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation; statements about the Company’s future plans, its goals and expectations, and the potential applications of its MyHeartTM platform are forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the management discussion and analysis section of Novoheart Holdings Inc.’s interim and most recent annual financial statement or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.

      Contact Information

      Ronald Li, CEO
      info@novoheart.com

      Babak Pedram, Investor Relations
      Virtus Advisory Group
      Tel: 416-995-8651
      bpedram@virtusadvisory.com

      For media enquiries or interviews, please contact:
      Josh Stanbury, Media Relations
      Tel. 416-628-7441
      media@novoheart.com "
      Avatar
      schrieb am 14.03.18 11:03:58
      Beitrag Nr. 29 ()

      http://www.aktie-x.de/2018/03/11-2018-verdopplungs-chance-da…





      Avatar
      schrieb am 29.03.18 16:03:18
      Beitrag Nr. 30 ()
      http://www.novoheart.com/global/press/detail/27
      "Novoheart Files Patent Application on Disease Modeling, Based on Landmark Research Conducted During Second Contract with Global Pharma Partner

      March 29, 2018 03:05 ET

      Novoheart Files Patent Application on Disease Modeling Based on Landmark Research Conducted During Second Contract with Global Pharma Partner


      Lack of reliable human disease models historically a major impediment to drug discovery and development as there is no reliable way of testing how drugs would act on human patients
      Novoheart building unique libraries of healthy and diseased engineered human heart tissues as well as chambers (“human heart-in-a-jar”), including a neurological disease model in contract with a Global Pharma partner
      Novoheart filing IP on creating human cardiac models for neurological diseases associated with fatal cardiac conditions affecting more than 1 in 20,000 people worldwide
      IP solely owned by Novoheart


      VANCOUVER, BRITISH COLUMBIA–(Marketwired - March 29, 2018) – Novoheart (“Novoheart” or the “Company”) (TSX VENTURE:NVH)(FRANKFURT:3NH) is pleased to announce that it has filed a patent application on the use of its proprietary MyHeartTM Platform of human bioengineered heart tissues to create disease models for neurological diseases in which afflicted patients suffer and often die from cardiac dysfunction. The IP, which is solely owned by Novoheart, was developed as part of the Company’s successfully completed second contract with a Global Pharma partner.

      The disease models will benefit patients and drug developers by providing a unique and robust platform for testing candidate therapeutics, ensuring that the best leads are chosen for clinical development. They also serve as an experimental model for unraveling pathological mechanisms of the diseases and for providing insights into potential drug targets.

      Historically, drug development has been greatly impeded by the lack of reliable disease models outside of the human body. The scientific community has depended heavily upon genetically engineered small mice: despite their well-recognized inadequacy in recapitulating human diseases, they have been persistently used in the absence of a superior alternative. Furthermore, certain diseases are unique to humans and cannot be modeled using animals.

      Novoheart’s MyHeartTM Platform, which can be personalized with patient-derived induced pluripotent stem cells (iPSCs), offers a revolutionary solution to this problem: with multicellular, 3D bioartificial heart tissues and chambers designed to reproduce clinical phenomena including arrhythmias and heart failure, disease symptoms can be readily detected and analyzed. This was successfully demonstrated with a neurological disease model created through the Global Pharma contract, whereby electrical and mechanical defects of the heart caused by a pathological gene mutation were captured by the human ventricular Cardiac Anisotropic Sheet (hvCAS), human ventricular Cardiac Tissue Strip (hvCTS) and the human ventricular Cardiac Organoid Chamber (hvCOC), otherwise known as the “human heart-in-a-jar”. The neurological disease is part of a family of related disorders, including various forms of hereditary ataxias, which similarly display cardiac complications and affect more than 1 in 20,000 people worldwide.

      “This technology can immediately be applied to drug screening as well as mechanistic studies to identify potential druggable targets for treating patients suffering from these debilitating diseases,” said Novoheart CSO Dr. Kevin Costa. “With its proven capability, Novoheart will continue to create human cardiac tissue disease models for various disorders and in doing so, help bring new treatments into the pipeline for such diseases by substantially reducing the costs and increasing the success rates.”

      “By enabling promising new drug candidates to be more quickly and accurately identified and advanced, our technology can bring tangible benefits to patients worldwide,” said Novoheart CEO Dr. Ronald Li. “As we continue to develop these models, we are building a novel library of heart tissues and chambers, as well as a drug response data repository for training machine learning algorithms, that can subsequently be used for developing highly targeted treatments. We believe that diseased and normal hearts, of different ethnic groups, on the MyHeartTM platform have the ability to revolutionize drug screening and development for advancing precision medicine.”


      About Novoheart:

      Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as 'human heart-in-a-jar', Novoheart’s bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.

      Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


      Cautionary Note Regarding Forward-Looking Statements

      Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation; statements about the Company's future plans, its goals and expectations, and the potential applications of its MyHeart™ platform are forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the management discussion and analysis section of Novoheart Holdings Inc.'s interim and most recent annual financial statement or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.


      Contact Information

      Novoheart
      Ronald Li, CEO
      info@novoheart.com

      Virtus Advisory Group
      Babak Pedram
      Investor Relations
      Tel: 416-995-8651
      bpedram@virtusadvisory.com

      For media enquiries or interviews, please contact:
      Josh Stanbury
      Media Relations
      Tel. 416-628-7441
      media@novoheart.com "


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      Novoheart - stem cell biotechnology - bioartificial human heart